Headache Center Fellowship
Leadership
- Program Director
- Headache Fellowship Program
For Program Information
901 Walnut Street
Suite 400
Philadelphia, PA 19107
The Jefferson Headache Center Fellowship program is dedicated to giving to the trainee the highest quality preparation so that he or she can make contributions to patient care and advance the level of knowledge of headache medicine.
The program will prepare the Fellow for a career in clinical headache practice or academic headache medicine. The Fellow will be exposed to outpatient and inpatient headache patient care, as well as clinical headache research involving epidemiology, Neurophysiology, and therapeutic studies. In addition, an optional pediatric headache rotation is available. Headache medicine is a unique subspecialty of neurology that requires knowledge not previously taught to trainees during their respective residency programs.
The Fellowship program consists of 12 months of training. The trainee will spend most of his or her time in the outpatient and inpatient headache units, but will have ample time to participate in research projects of their choosing. The trainee will see patients 4 days/week, with 2 half days/week devoted to research.
The Headache Center
The Jefferson Headache Center is one of a very few academic headache centers in the country.
In addition to treating patients, the Jefferson Headache Center is a teaching facility that gives residents the highest quality of preparation so that they can make contributions to patient care and advance the level of knowledge of headache medicine.
Publications
- Risk factors for migraine disease progression: a narrative review for a patient-centered approach
- Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
- The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review
- Optimized Acute Treatment of Migraine Is Associated with Greater Productivity in People with Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
- Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies (The Journal of Headache and Pain, (2021), 22, 1, (141), 10.1186/s10194-021-01351-2)